How to Buy lincoln Shares on Fincept?
You can buy Lincoln Pharmaceuticals Limited shares on Different Brokers & Banks by creating an account and completing KYC verification online.
NSE: Lincoln Pharmaceuticals Limited Share Price Today, Share Analysis, Latest Updates & Insights | Fincept
Stay informed with the latest announcements for Lincoln, including updates on board meetings and corporate actions.
Lincoln Pharmaceuticals Limited - https://www.lincolnpharma.com
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East Asia. The company was incorporated in 1979 and is based in Ahmedabad, India.
Lincoln Pharmaceuticals Limited Share Price Today
709.80
OPEN
715.00
HIGH
691.55
LOW
699.30
CLOSE
35 K
VOLUME
1,612 Cr
Market Cap
159071
Average Volume
Healthcare
Sector
NSI
Exchange
Lincoln Pharmaceuticals Limited Share Analysis & 2025 Insights
Investor Presentations
| Date | Description | Download |
|---|
SIP
Lumpsum
Invested Amount: ₹
Estimated Returns: ₹
Total Value: ₹
NSE: LINCOLN Stock Actions
Company |
Symbol |
ISIN |
Subject |
Ex Date |
Face Value |
Broadcast Date |
|---|---|---|---|---|---|---|
Lincoln Pharmaceuticals Limited |
LINCOLN |
INE405C01035 |
Dividend - Rs 1.80 Per Share |
13 Sep 2024 |
10 |
N/A |
Lincoln Pharmaceuticals Limited |
LINCOLN |
INE405C01035 |
Annual General Meeting/Dividend - Rs 1.50 Per Share |
15 Sep 2023 |
10 |
N/A |
Lincoln Pharmaceuticals Limited |
LINCOLN |
INE405C01035 |
Annual General Meeting/Dividend - Rs 1.50 Per Share |
15 Sep 2022 |
10 |
N/A |
Lincoln Pharmaceuticals Limited |
LINCOLN |
INE405C01035 |
Dividend - Rs 1.50 Per Share |
16 Sep 2021 |
10 |
N/A |
Lincoln Pharmaceuticals Limited |
LINCOLN |
INE405C01035 |
Annual General Meeting |
17 Sep 2020 |
10 |
N/A |
NSE: LINCOLN Recent Announcements
Symbol |
Date |
Description |
Industry |
|---|---|---|---|
LINCOLN |
03 Jan 2025, 12:58:49 |
General Updates |
N/A |
LINCOLN |
25 Dec 2024, 15:02:20 |
Trading Window-XBRL |
N/A |
LINCOLN |
25 Dec 2024, 14:55:16 |
Trading Window |
N/A |
LINCOLN |
20 Dec 2024, 17:33:06 |
Reply to Clarification- Financial results |
N/A |
LINCOLN |
11 Dec 2024, 20:32:55 |
Clarification - Financial Results |
N/A |
NSE: LINCOLN Corporate Governance
Name |
Symbol |
Timestamp |
Submission Date |
XBRL Document |
|---|---|---|---|---|
Lincoln Pharmaceuticals Limited |
LINCOLN |
08 Jan 2025, 14:20:00 |
08 Jan 2025, 14:20:00 |
|
Lincoln Pharmaceuticals Limited |
LINCOLN |
15 Oct 2024, 11:49:00 |
15 Oct 2024, 11:49:00 |
|
Lincoln Pharmaceuticals Limited |
LINCOLN |
08 Jul 2024, 10:46:00 |
08 Jul 2024, 10:46:00 |
|
Lincoln Pharmaceuticals Limited |
LINCOLN |
25 Apr 2024, 16:10:00 |
25 Apr 2024, 16:30:00 |
|
Lincoln Pharmaceuticals Limited |
LINCOLN |
18 Jan 2024, 12:45:00 |
18 Jan 2024, 13:15:00 |
NSE: LINCOLN Detailed Governance
Category |
Date of Birth |
Date of Initial Appointment |
DIN |
Director Name |
Status |
|---|---|---|---|---|---|
Chairperson & Non-Executive Director |
04 Mar 1944 |
16 Aug 1995 |
02769085 |
Kishorbhai Meghjibhai Shah |
Active |
Executive Director-MD |
26 Jan 1954 |
20 Jan 1995 |
00104706 |
Mahendra Gulabdas Patel |
Active |
Executive Director |
08 Dec 1958 |
20 Jan 1995 |
00104834 |
Hashmukh Ishwarlal Patel |
Active |
Executive Director |
26 Jun 1982 |
14 Nov 2014 |
02319308 |
Munjal Mahendra Patel |
Active |
Executive Director |
12 May 1981 |
14 Nov 2014 |
01309017 |
Ashish Rajnibhai Patel |
Active |
NSE: LINCOLN Board Meetings
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
|---|---|---|---|---|---|
Board Meeting Intimation |
LINCOLN |
N/A |
INE405C01035 |
Lincoln Pharmaceuticals Limited |
05 Nov 2024, 11:24:43 |
Financial Results |
LINCOLN |
N/A |
INE405C01035 |
Lincoln Pharmaceuticals Limited |
30 Jul 2024, 15:59:01 |
LINCOLN PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 16-May-2024 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2024 and Dividend. |
LINCOLN |
N/A |
INE405C01035 |
Lincoln Pharmaceuticals Limited |
08 May 2024, 17:36:43 |
LINCOLN PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 08-Feb-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended December 2023 . |
LINCOLN |
N/A |
INE405C01035 |
Lincoln Pharmaceuticals Limited |
25 Jan 2024, 15:12:16 |
LINCOLN PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 02-Nov-2023 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2023 . |
LINCOLN |
N/A |
INE405C01035 |
Lincoln Pharmaceuticals Limited |
23 Oct 2023, 14:25:02 |
NSE: LINCOLN Event Calendar
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
Description |
|---|---|---|---|---|---|---|
Financial Results |
LINCOLN |
- |
INE405C01035 |
Lincoln Pharmaceuticals Limited |
05 Nov 2024, 00:00:00 |
Intimation of Board Meeting to consider and approve the unaudited (Standalone & Consolidated) financial results for the period ended September 30, 2024. |
Financial Results |
LINCOLN |
- |
INE405C01035 |
Lincoln Pharmaceuticals Limited |
30 Jul 2024, 00:00:00 |
Intimation of Board Meeting to consider and approve the unaudited (standalone & consolidated) financial results for the period ended Jun 30, 2024 along with any other business, if any. |
Financial Results/Dividend |
LINCOLN |
- |
INE405C01035 |
Lincoln Pharmaceuticals Limited |
08 May 2024, 00:00:00 |
To consider and approve the Audited financial results (Standalone & Consolidated)of the Company for the Quarter and Year ended March 31, 2024 and recommendation of dividend if any. |
Financial Results |
LINCOLN |
- |
INE405C01035 |
Lincoln Pharmaceuticals Limited |
25 Jan 2024, 00:00:00 |
Intimation of Board meeting to consider and approve the unaudited (standalone & Consolidated) financial results for the period ended December 31, 2023. |
Financial Results |
LINCOLN |
- |
INE405C01035 |
Lincoln Pharmaceuticals Limited |
23 Oct 2023, 00:00:00 |
Intimation of Board Meeting to consider and approve the financial results for the period ended September 30, 2023 |
NSE: LINCOLN Balance Sheet Data In (Cr)
| date | period_type | Ordinary Shares Number | Share Issued | Net Debt | Total Debt | Tangible Book Value | Invested Capital | Working Capital | Net Tangible Assets | Common Stock Equity | Total Capitalization | Total Equity Gross Minority Interest | Minority Interest | Stockholders Equity | Other Equity Interest | Retained Earnings | Additional Paid In Capital | Capital Stock | Common Stock | Total Liabilities Net Minority Interest | Total Non Current Liabilities Net Minority Interest | Other Non Current Liabilities | Non Current Pension And Other Postretirement Benefit Plans | Non Current Deferred Revenue | Non Current Deferred Taxes Liabilities | Long Term Debt And Capital Lease Obligation | Long Term Debt | Long Term Provisions | Current Liabilities | Other Current Liabilities | Current Deferred Taxes Liabilities | Current Debt And Capital Lease Obligation | Current Debt | Pensionand Other Post Retirement Benefit Plans Current | Current Provisions | Payables | Other Payable | Dividends Payable | Total Tax Payable | Accounts Payable | Total Assets | Total Non Current Assets | Other Non Current Assets | Non Current Prepaid Assets | Investmentin Financial Assets | Held To Maturity Securities | Available For Sale Securities | Long Term Equity Investment | Investments In Other Ventures Under Equity Method | Investmentsin Subsidiariesat Cost | Goodwill And Other Intangible Assets | Other Intangible Assets | Goodwill | Net PPE | Accumulated Depreciation | Gross PPE | Construction In Progress | Other Properties | Machinery Furniture Equipment | Buildings And Improvements | Land And Improvements | Properties | Current Assets | Other Current Assets | Hedging Assets Current | Restricted Cash | Prepaid Assets | Inventory | Other Inventories | Finished Goods | Work In Process | Raw Materials | Other Receivables | Accounts Receivable | Allowance For Doubtful Accounts Receivable | Gross Accounts Receivable | Cash Cash Equivalents And Short Term Investments | Other Short Term Investments | Cash And Cash Equivalents | Cash Financial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30T00:00:00 | quarterly | 20,029,728.00 | 20,029,728.00 | 0.00 | 13,554,000.00 | 6,389,421,000.00 | 6,406,185,000.00 | 4,026,957,000.00 | 6,389,421,000.00 | 6,392,631,000.00 | 6,392,631,000.00 | 6,392,631,000.00 | 0.00 | 6,392,631,000.00 | 6,192,334,000.00 | 0.00 | 0.00 | 200,297,000.00 | 200,297,000.00 | 1,405,295,000.00 | 200,930,000.00 | 0.00 | 0.00 | 0.00 | 150,941,000.00 | 0.00 | 0.00 | 0.00 | 1,204,365,000.00 | 33,928,000.00 | 0.00 | 13,554,000.00 | 13,554,000.00 | 0.00 | 44,989,000.00 | 955,215,000.00 | 0.00 | 0.00 | 4,348,000.00 | 950,867,000.00 | 7,797,926,000.00 | 2,566,604,000.00 | 36,937,000.00 | 0.00 | 5,162,000.00 | 0.00 | 5,162,000.00 | 0.00 | 0.00 | 0.00 | 3,210,000.00 | 3,210,000.00 | 0.00 | 1,833,870,000.00 | 0.00 | 1,833,870,000.00 | 65,558,000.00 | 1,768,312,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5,231,322,000.00 | 133,170,000.00 | 0.00 | 0.00 | 0.00 | 847,729,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 461,850,000.00 | 1,784,546,000.00 | 0.00 | 0.00 | 2,004,027,000.00 | 1,902,678,000.00 | 101,349,000.00 | 0.00 |
| 2024-03-31T00:00:00 | quarterly | 20,029,728.00 | 20,029,728.00 | 0.00 | 10,668,000.00 | 5,925,099,000.00 | 5,939,027,000.00 | 3,544,631,000.00 | 5,925,099,000.00 | 5,928,359,000.00 | 5,928,359,000.00 | 5,928,359,000.00 | 0.00 | 5,928,359,000.00 | 5,728,062,000.00 | 5,074,587,000.00 | 646,166,000.00 | 200,297,000.00 | 200,297,000.00 | 1,074,545,000.00 | 151,774,000.00 | 0.00 | 971,000.00 | 0.00 | 114,558,000.00 | 0.00 | 0.00 | 971,000.00 | 922,771,000.00 | 27,359,000.00 | 712,000.00 | 10,668,000.00 | 10,668,000.00 | 0.00 | 35,202,000.00 | 862,815,000.00 | 136,586,000.00 | 1,832,000.00 | 712,000.00 | 724,397,000.00 | 7,002,904,000.00 | 2,535,502,000.00 | 1,000.00 | 5,785,000.00 | 35,000.00 | 0.00 | 35,000.00 | 0.00 | 0.00 | 0.00 | 3,260,000.00 | 3,260,000.00 | 0.00 | 1,865,491,000.00 | -563,679,000.00 | 2,429,170,000.00 | 75,486,000.00 | 218,051,000.00 | 1,333,193,000.00 | 602,205,000.00 | 200,235,000.00 | 0.00 | 4,467,402,000.00 | 161,055,000.00 | 0.00 | 3,008,000.00 | 113,665,000.00 | 771,681,000.00 | 89,189,000.00 | 375,656,000.00 | 82,813,000.00 | 224,023,000.00 | 436,920,000.00 | 1,617,669,000.00 | -21,559,000.00 | 1,639,228,000.00 | 1,524,459,000.00 | 1,466,987,000.00 | 57,472,000.00 | 57,472,000.00 |
| 2024-03-31T00:00:00 | annual | 20,029,728.00 | 20,029,728.00 | 0.00 | 10,668,000.00 | 5,925,099,000.00 | 5,939,027,000.00 | 3,544,631,000.00 | 5,925,099,000.00 | 5,928,359,000.00 | 5,928,359,000.00 | 5,928,359,000.00 | 0.00 | 5,928,359,000.00 | 5,728,062,000.00 | 5,074,587,000.00 | 646,166,000.00 | 200,297,000.00 | 200,297,000.00 | 1,074,545,000.00 | 151,774,000.00 | 0.00 | 971,000.00 | 0.00 | 114,558,000.00 | 0.00 | 0.00 | 971,000.00 | 922,771,000.00 | 27,359,000.00 | 712,000.00 | 10,668,000.00 | 10,668,000.00 | 0.00 | 35,202,000.00 | 862,815,000.00 | 136,586,000.00 | 1,832,000.00 | 712,000.00 | 724,397,000.00 | 7,002,904,000.00 | 2,535,502,000.00 | 1,000.00 | 5,785,000.00 | 35,000.00 | 0.00 | 35,000.00 | 0.00 | 0.00 | 0.00 | 3,260,000.00 | 3,260,000.00 | 0.00 | 1,865,491,000.00 | -563,679,000.00 | 2,429,170,000.00 | 75,486,000.00 | 218,051,000.00 | 1,333,193,000.00 | 602,205,000.00 | 200,235,000.00 | 0.00 | 4,467,402,000.00 | 161,055,000.00 | 0.00 | 3,008,000.00 | 113,665,000.00 | 771,681,000.00 | 89,189,000.00 | 375,656,000.00 | 82,813,000.00 | 224,023,000.00 | 436,920,000.00 | 1,617,669,000.00 | -21,559,000.00 | 1,639,228,000.00 | 1,524,459,000.00 | 1,466,987,000.00 | 57,472,000.00 | 57,472,000.00 |
| 2023-09-30T00:00:00 | quarterly | 20,029,728.00 | 20,029,728.00 | 0.00 | 8,972,000.00 | 5,456,792,000.00 | 5,468,859,000.00 | 3,357,793,000.00 | 5,456,792,000.00 | 5,459,887,000.00 | 5,459,887,000.00 | 5,459,887,000.00 | 0.00 | 5,459,887,000.00 | 5,259,590,000.00 | 0.00 | 0.00 | 200,297,000.00 | 200,297,000.00 | 1,172,799,000.00 | 140,984,000.00 | 0.00 | 0.00 | 0.00 | 94,180,000.00 | 0.00 | 0.00 | 0.00 | 1,031,815,000.00 | 28,339,000.00 | 0.00 | 8,972,000.00 | 8,972,000.00 | 0.00 | 42,553,000.00 | 825,364,000.00 | 0.00 | 0.00 | 51,165,000.00 | 774,199,000.00 | 6,632,686,000.00 | 2,243,078,000.00 | 26,757,000.00 | 0.00 | 69,720,000.00 | 0.00 | 69,720,000.00 | 0.00 | 0.00 | 0.00 | 3,095,000.00 | 3,095,000.00 | 0.00 | 1,561,024,000.00 | 0.00 | 1,561,024,000.00 | 91,431,000.00 | 1,469,593,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4,389,608,000.00 | 103,629,000.00 | 0.00 | 0.00 | 0.00 | 655,862,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 144,000,000.00 | 1,731,052,000.00 | 0.00 | 0.00 | 1,755,065,000.00 | 1,602,995,000.00 | 152,070,000.00 | 0.00 |
| 2023-03-31T00:00:00 | quarterly | 20,029,728.00 | 20,029,728.00 | 0.00 | 19,972,000.00 | 5,021,798,000.00 | 5,044,716,000.00 | 2,950,676,000.00 | 5,021,798,000.00 | 5,024,744,000.00 | 5,024,744,000.00 | 5,024,744,000.00 | 0.00 | 5,024,744,000.00 | 4,824,449,000.00 | 4,176,583,000.00 | 646,166,000.00 | 200,297,000.00 | 200,297,000.00 | 849,458,000.00 | 128,006,000.00 | 1,000.00 | 1,389,000.00 | 47,212,000.00 | 79,405,000.00 | 0.00 | 0.00 | 0.00 | 721,452,000.00 | 20,917,000.00 | 8,815,000.00 | 19,972,000.00 | 19,972,000.00 | 0.00 | 38,898,000.00 | 645,560,000.00 | 135,199,000.00 | 1,692,000.00 | 8,815,000.00 | 508,669,000.00 | 5,874,202,000.00 | 2,202,074,000.00 | 2,000.00 | 13,636,000.00 | 32,000.00 | 0.00 | 32,000.00 | 0.00 | 0.00 | 0.00 | 2,946,000.00 | 2,946,000.00 | 0.00 | 1,584,849,000.00 | -460,977,000.00 | 2,045,826,000.00 | 82,516,000.00 | 53,732,000.00 | 1,141,562,000.00 | 580,656,000.00 | 187,360,000.00 | 0.00 | 3,672,128,000.00 | 113,047,000.00 | 264,000.00 | 118,266,000.00 | 90,292,000.00 | 700,279,000.00 | 92,489,000.00 | 309,709,000.00 | 91,754,000.00 | 206,327,000.00 | 261,527,000.00 | 1,363,308,000.00 | -15,064,000.00 | 1,378,372,000.00 | 1,138,192,000.00 | 1,087,672,000.00 | 50,520,000.00 | 50,520,000.00 |
| 2023-03-31T00:00:00 | annual | 20,029,728.00 | 20,029,728.00 | 0.00 | 19,972,000.00 | 5,021,798,000.00 | 5,044,716,000.00 | 2,950,676,000.00 | 5,021,798,000.00 | 5,024,744,000.00 | 5,024,744,000.00 | 5,024,744,000.00 | 0.00 | 5,024,744,000.00 | 4,824,449,000.00 | 4,176,583,000.00 | 646,166,000.00 | 200,297,000.00 | 200,297,000.00 | 849,458,000.00 | 128,006,000.00 | 1,000.00 | 1,389,000.00 | 47,212,000.00 | 79,405,000.00 | 0.00 | 0.00 | 0.00 | 721,452,000.00 | 20,917,000.00 | 8,815,000.00 | 19,972,000.00 | 19,972,000.00 | 0.00 | 38,898,000.00 | 645,560,000.00 | 135,199,000.00 | 1,692,000.00 | 8,815,000.00 | 508,669,000.00 | 5,874,202,000.00 | 2,202,074,000.00 | 2,000.00 | 13,636,000.00 | 32,000.00 | 0.00 | 32,000.00 | 0.00 | 0.00 | 0.00 | 2,946,000.00 | 2,946,000.00 | 0.00 | 1,584,849,000.00 | -460,977,000.00 | 2,045,826,000.00 | 82,516,000.00 | 53,732,000.00 | 1,141,562,000.00 | 580,656,000.00 | 187,360,000.00 | 0.00 | 3,672,128,000.00 | 113,047,000.00 | 264,000.00 | 118,266,000.00 | 90,292,000.00 | 700,279,000.00 | 92,489,000.00 | 309,709,000.00 | 91,754,000.00 | 206,327,000.00 | 261,527,000.00 | 1,363,308,000.00 | -15,064,000.00 | 1,378,372,000.00 | 1,138,192,000.00 | 1,087,672,000.00 | 50,520,000.00 | 50,520,000.00 |
| 2022-03-31T00:00:00 | annual | 20,029,728.00 | 20,029,728.00 | 0.00 | 20,436,000.00 | 4,324,947,000.00 | 4,349,210,000.00 | 2,623,635,000.00 | 4,324,947,000.00 | 4,328,774,000.00 | 4,328,774,000.00 | 4,328,774,000.00 | 0.00 | 4,328,774,000.00 | 4,128,478,000.00 | 3,482,635,000.00 | 646,166,000.00 | 200,297,000.00 | 200,297,000.00 | 1,014,798,000.00 | 109,936,000.00 | 1,000.00 | 0.00 | 45,391,000.00 | 64,545,000.00 | 0.00 | 0.00 | 0.00 | 904,862,000.00 | 12,319,000.00 | 42,767,000.00 | 20,436,000.00 | 20,436,000.00 | 0.00 | 26,582,000.00 | 856,746,000.00 | 95,538,000.00 | 1,769,000.00 | 42,767,000.00 | 716,672,000.00 | 5,343,572,000.00 | 1,815,075,000.00 | 45,779,000.00 | 16,872,000.00 | 26,000.00 | 0.00 | 26,000.00 | 0.00 | 0.00 | 0.00 | 3,827,000.00 | 3,827,000.00 | 0.00 | 1,506,341,000.00 | -384,511,000.00 | 1,890,852,000.00 | 191,363,000.00 | 42,105,000.00 | 992,453,000.00 | 478,611,000.00 | 186,320,000.00 | 0.00 | 3,528,497,000.00 | 159,597,000.00 | 1,549,000.00 | 4,837,000.00 | 124,594,000.00 | 727,420,000.00 | 98,174,000.00 | 271,853,000.00 | 87,216,000.00 | 270,177,000.00 | 356,255,000.00 | 1,159,415,000.00 | -16,840,000.00 | 1,176,255,000.00 | 1,154,427,000.00 | 1,085,087,000.00 | 69,340,000.00 | 69,340,000.00 |
| 2021-03-31T00:00:00 | annual | 20,000,000.00 | 20,000,000.00 | 0.00 | 5,197,000.00 | 3,659,943,000.00 | 3,669,120,000.00 | 2,329,103,000.00 | 3,659,943,000.00 | 3,663,923,000.00 | 3,665,368,000.00 | 3,663,923,000.00 | 4,079,000.00 | 3,663,923,000.00 | 0.00 | 2,824,084,000.00 | 646,166,000.00 | 200,297,000.00 | 200,297,000.00 | 859,669,000.00 | 101,266,000.00 | -3,000.00 | 0.00 | 42,916,000.00 | 56,905,000.00 | 1,445,000.00 | 1,445,000.00 | 0.00 | 758,403,000.00 | 9,975,000.00 | 31,588,000.00 | 3,752,000.00 | 3,752,000.00 | 1,599,000.00 | 21,809,000.00 | 665,851,000.00 | 93,443,000.00 | 1,748,000.00 | 31,588,000.00 | 570,660,000.00 | 4,523,592,000.00 | 1,436,086,000.00 | 9,000.00 | 30,636,000.00 | 1,040,000.00 | 14,000.00 | 1,026,000.00 | 815,000.00 | 26,000.00 | 815,000.00 | 3,980,000.00 | 3,980,000.00 | 92,256,000.00 | 1,144,881,000.00 | -306,576,000.00 | 1,451,457,000.00 | 42,476,000.00 | 30,513,000.00 | 847,980,000.00 | 357,916,000.00 | 172,572,000.00 | 0.00 | 3,087,506,000.00 | 13,000.00 | 831,000.00 | 24,028,000.00 | 188,060,000.00 | 466,128,000.00 | 67,683,000.00 | 168,114,000.00 | 55,272,000.00 | 175,059,000.00 | 353,862,000.00 | 1,133,485,000.00 | -18,583,000.00 | 1,152,068,000.00 | 921,099,000.00 | 806,716,000.00 | 114,383,000.00 | 114,383,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 281,518,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3,819,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 40,524,000.00 | 0.00 | 8,489,000.00 | 8,489,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4,438,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14,000.00 | 0.00 | 815,000.00 | 26,000.00 | 815,000.00 | 0.00 | 0.00 | 92,256,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 167,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: LINCOLN Cash Flow Data In (Cr)
| date | period_type | Free Cash Flow | Repayment Of Debt | Issuance Of Debt | Capital Expenditure | End Cash Position | Other Cash Adjustment Outside Changein Cash | Beginning Cash Position | Changes In Cash | Financing Cash Flow | Interest Paid Cff | Cash Dividends Paid | Common Stock Dividend Paid | Net Issuance Payments Of Debt | Net Short Term Debt Issuance | Short Term Debt Payments | Short Term Debt Issuance | Net Long Term Debt Issuance | Long Term Debt Payments | Long Term Debt Issuance | Investing Cash Flow | Net Other Investing Changes | Interest Received Cfi | Dividends Received Cfi | Net Investment Purchase And Sale | Sale Of Investment | Purchase Of Investment | Net Business Purchase And Sale | Sale Of Business | Net Intangibles Purchase And Sale | Purchase Of Intangibles | Net PPE Purchase And Sale | Sale Of PPE | Purchase Of PPE | Operating Cash Flow | Taxes Refund Paid | Change In Working Capital | Change In Other Current Liabilities | Change In Other Current Assets | Change In Payable | Change In Inventory | Change In Receivables | Other Non Cash Items | Provisionand Write Offof Assets | Depreciation And Amortization | Amortization Cash Flow | Depreciation | Gain Loss On Investment Securities | Gain Loss On Sale Of PPE | Net Income From Continuing Operations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 236,042,000.00 | -209,019,000.00 | 200,000,000.00 | -396,130,000.00 | 57,472,000.00 | 0.00 | 50,520,000.00 | 6,952,000.00 | -51,804,000.00 | -12,740,000.00 | -30,045,000.00 | 0.00 | -9,019,000.00 | -9,019,000.00 | -209,019,000.00 | 200,000,000.00 | 0.00 | 0.00 | 0.00 | -573,416,000.00 | 215,518,000.00 | 89,907,000.00 | 44,000.00 | -248,048,000.00 | 748,262,000.00 | -996,310,000.00 | 0.00 | 0.00 | -1,371,000.00 | -1,371,000.00 | -393,859,000.00 | 900,000.00 | -394,759,000.00 | 632,172,000.00 | -261,508,000.00 | -161,165,000.00 | 725,000.00 | -42,062,000.00 | 215,728,000.00 | -71,402,000.00 | -260,856,000.00 | -55,582,000.00 | 6,495,000.00 | 106,247,000.00 | 1,057,000.00 | 105,190,000.00 | -227,501,000.00 | 2,760,000.00 | 1,222,426,000.00 |
| 2023-03-31T00:00:00 | annual | 249,799,000.00 | -195,018,000.00 | 193,574,000.00 | -142,820,000.00 | 50,520,000.00 | 0.00 | 69,340,000.00 | -18,820,000.00 | -45,013,000.00 | -13,524,000.00 | -30,045,000.00 | 0.00 | -1,444,000.00 | -1,444,000.00 | -195,018,000.00 | 193,574,000.00 | 0.00 | 0.00 | 0.00 | -366,426,000.00 | -150,203,000.00 | 9,255,000.00 | 0.00 | 106,144,000.00 | 738,013,000.00 | -631,869,000.00 | 0.00 | 0.00 | -232,000.00 | -232,000.00 | -135,531,000.00 | 7,057,000.00 | -142,588,000.00 | 392,619,000.00 | -296,098,000.00 | -313,735,000.00 | 12,965,000.00 | 43,694,000.00 | -205,142,000.00 | 27,141,000.00 | -202,119,000.00 | -41,410,000.00 | -1,776,000.00 | 91,661,000.00 | 1,113,000.00 | 90,548,000.00 | -50,061,000.00 | -760,000.00 | 1,004,798,000.00 |
| 2022-03-31T00:00:00 | annual | 306,067,000.00 | -5,197,000.00 | 20,000,000.00 | -455,252,000.00 | 69,340,000.00 | 0.00 | 114,384,000.00 | -45,044,000.00 | -25,561,000.00 | -10,364,000.00 | -30,000,000.00 | -30,000,000.00 | 14,803,000.00 | 20,000,000.00 | 0.00 | 20,000,000.00 | -5,197,000.00 | -5,197,000.00 | 0.00 | -780,802,000.00 | -107,556,000.00 | 26,294,000.00 | 0.00 | -125,295,000.00 | 405,178,000.00 | -530,473,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | -454,459,000.00 | 793,000.00 | -455,252,000.00 | 761,319,000.00 | -236,964,000.00 | 24,045,000.00 | -18,676,000.00 | 182,767,000.00 | 145,929,000.00 | -261,292,000.00 | -31,192,000.00 | -35,772,000.00 | -1,743,000.00 | 80,878,000.00 | 1,350,000.00 | 79,528,000.00 | -36,835,000.00 | 1,295,000.00 | 959,393,000.00 |
| 2021-03-31T00:00:00 | annual | 605,192,000.00 | -45,543,000.00 | 0.00 | -87,503,000.00 | 114,383,000.00 | 0.00 | 121,414,000.00 | -7,031,000.00 | -57,453,000.00 | -11,910,000.00 | 0.00 | 0.00 | -45,543,000.00 | -38,332,000.00 | -38,332,000.00 | 0.00 | -7,211,000.00 | -7,211,000.00 | 0.00 | -642,273,000.00 | -4,439,000.00 | 20,311,000.00 | 280,000.00 | -439,985,000.00 | 105,042,000.00 | -545,027,000.00 | 500,000.00 | 500,000.00 | 0.00 | 0.00 | -86,853,000.00 | 650,000.00 | -87,503,000.00 | 692,695,000.00 | -194,911,000.00 | 2,037,000.00 | 48,901,000.00 | -6,819,000.00 | 55,496,000.00 | 7,832,000.00 | -100,827,000.00 | 1,325,000.00 | 910,000.00 | 75,603,000.00 | 1,383,000.00 | 74,220,000.00 | -30,004,000.00 | 527,000.00 | 837,208,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | -72,334,000.00 | -72,334,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | -22,743,000.00 | -30,843,000.00 | 8,100,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: LINCOLN Income Statement Data In (Cr)
| date | period_type | Tax Effect Of Unusual Items | Tax Rate For Calcs | Normalized EBITDA | Total Unusual Items | Total Unusual Items Excluding Goodwill | Net Income From Continuing Operation Net Minority Interest | Reconciled Depreciation | Reconciled Cost Of Revenue | EBITDA | EBIT | Net Interest Income | Interest Expense | Interest Income | Normalized Income | Net Income From Continuing And Discontinued Operation | Total Expenses | Rent Expense Supplemental | Diluted Average Shares | Basic Average Shares | Diluted EPS | Basic EPS | Diluted NI Availto Com Stockholders | Net Income Common Stockholders | Otherunder Preferred Stock Dividend | Net Income | Minority Interests | Net Income Including Noncontrolling Interests | Net Income Continuous Operations | Tax Provision | Pretax Income | Other Non Operating Income Expenses | Special Income Charges | Other Special Charges | Write Off | Net Non Operating Interest Income Expense | Total Other Finance Cost | Interest Expense Non Operating | Interest Income Non Operating | Operating Income | Operating Expense | Other Operating Expenses | Depreciation And Amortization In Income Statement | Amortization | Depreciation Income Statement | Selling General And Administration | Selling And Marketing Expense | General And Administrative Expense | Rent And Landing Fees | Gross Profit | Cost Of Revenue | Total Revenue | Operating Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 5.31 | 0.00 | 111.37 | 22.45 | 22.45 | 93.30 | 10.62 | 280.02 | 133.81 | 123.19 | 5.56 | 0.95 | 7.02 | 76.17 | 93.30 | 481.60 | 0.24 | 2.00 | 2.00 | 0.00 | 0.00 | 93.30 | 93.30 | 0.00 | 93.30 | 0.00 | 93.30 | 93.30 | 28.94 | 122.24 | 34.42 | -0.30 | 0.30 | 0.00 | 5.56 | 0.52 | 0.95 | 7.02 | 89.62 | 201.58 | 39.96 | 10.62 | 0.11 | 10.52 | 41.25 | 23.35 | 17.91 | 0.24 | 291.20 | 280.02 | 571.22 | 571.22 |
| 2023-03-31T00:00:00 | annual | 1.30 | 0.00 | 106.53 | 4.75 | 4.75 | 72.90 | 9.17 | 243.09 | 111.28 | 102.12 | 4.14 | 1.64 | 6.17 | 69.45 | 72.90 | 424.28 | 0.17 | 2.00 | 2.00 | 0.00 | 0.00 | 72.90 | 72.90 | 0.00 | 72.90 | 0.00 | 72.90 | 72.90 | 27.58 | 100.48 | 22.47 | -0.26 | 0.26 | 0.00 | 4.14 | 0.39 | 1.64 | 6.17 | 80.68 | 181.19 | 34.53 | 9.17 | 0.11 | 9.05 | 37.95 | 18.04 | 19.91 | 0.17 | 261.87 | 243.09 | 504.95 | 504.95 |
| 2022-03-31T00:00:00 | annual | 0.79 | 0.00 | 102.10 | 2.85 | 2.85 | 69.36 | 8.09 | 219.79 | 104.95 | 96.86 | 3.58 | 0.92 | 5.03 | 67.29 | 69.36 | 379.80 | 0.94 | 2.00 | 2.00 | 0.00 | 0.00 | 69.36 | 69.36 | 0.00 | 69.36 | 0.00 | 69.36 | 69.36 | 26.58 | 95.94 | 10.00 | -0.83 | 0.13 | 0.70 | 3.58 | 0.53 | 0.92 | 5.03 | 88.40 | 160.01 | 29.57 | 8.09 | 0.14 | 7.95 | 35.44 | 16.82 | 18.63 | 0.94 | 248.41 | 219.79 | 468.20 | 468.20 |
| 2021-03-31T00:00:00 | annual | 0.72 | 0.00 | 89.69 | 2.79 | 2.79 | 62.25 | 7.56 | 198.88 | 92.48 | 84.92 | 0.68 | 1.20 | 2.24 | 60.18 | 62.25 | 334.95 | 0.14 | 2.00 | 2.00 | 0.00 | 0.00 | 62.25 | 62.25 | 0.00 | 62.25 | -0.03 | 62.25 | 62.25 | 21.47 | 83.72 | 5.66 | -0.18 | 0.18 | 0.00 | 0.68 | 0.36 | 1.20 | 2.24 | 79.80 | 136.07 | 29.83 | 7.56 | 0.14 | 7.42 | 34.91 | 20.39 | 14.52 | 0.14 | 215.87 | 198.88 | 414.75 | 414.75 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
FII & DII Data (In Cr)
| Date | FII Gross Purchase | FII Gross Sales | FII Net Purchase / Sales | DII Gross Purchase | DII Gross Sales | DII Net Purchase / Sales |
|---|---|---|---|---|---|---|
| 2025-02-03 | 12,505.92 | 16,464.29 | -3,958.37 | 19,319.48 | 16,611.25 | 2,708.23 |
| 2025-01-30 | 10,513.63 | 15,096.58 | -4,582.95 | 13,934.35 | 11,768.46 | 2,165.89 |
| 2025-01-29 | 7,644.40 | 10,230.83 | -2,586.43 | 12,871.38 | 11,078.67 | 1,792.71 |
| 2025-01-27 | 9,488.57 | 14,504.03 | -5,015.46 | 16,503.43 | 9,861.28 | 6,642.15 |
| 2025-01-24 | 11,230.47 | 13,988.96 | -2,758.49 | 12,835.41 | 10,433.10 | 2,402.31 |
| 2025-01-23 | 13,316.55 | 18,779.07 | -5,462.52 | 14,412.73 | 10,700.18 | 3,712.55 |
| 2025-01-22 | 12,936.64 | 16,962.89 | -4,026.25 | 15,437.18 | 11,796.96 | 3,640.22 |
Piotroski F-Score
5/9
0
1
2
3
4
5
6
7
8
9
Key Metrics
EPS
48.24
P/E
16.68325
P/B
2.719121
Dividend Yield
0.29%
Market Cap
1,611.99 Cr.
Face Value
295.978
Book Value
295.978
ROE
16.54%
EBITDA Growth
101.64 Cr.
Debt/Equity
0.18
Short Term
Subscribe to unlock this feature
Medium Term
Subscribe to unlock this feature
Long Term
Subscribe to unlock this feature
Yearly Stock Performance Heatmap
Latest Updates
Ashoka Buildcon Arm Signs Rs 1,391 Crore Pact With NHAI
Ashoka Buildcon Ltd. announced on Monday, via an exchange filing, that its wholly owned subsidiary, Ashoka Bowaichandi Guskara Road Pvt Ltd., has exec...
Budget 2025: Rahul Bajoria On Addressing Income Growth And Consumption Trends
"However, discretionary, high-value consumption is taking a step back due to income growth settling at high single digits." Over the past fe...
FPIs Stay Net Sellers, Sell Stocks Worth Rs 2,575 Crore
Foreign portfolio investors stayed net sellers for the second straight session on Monday and sold stocks worth approximately Rs 2,575.1 crore, accordi...
Budget 2025: AMFI Seeks Tax Policy Reforms To Drive Mutual Fund Investments In 15-Point Proposal
The Association of Mutual Funds of India on Monday released a 15-point proposal for Union Budget 2025-26 requesting changes in tax policies that are i...
Apple iPhone SE 4: Price To Features, 11 Things You Need To Know
iPhone 16e (Not iPhone SE 4): If recent reports are to be believed, Apple may discontinue the SE label and rename iPhone SE 4 as iPhone 16e. Most Affo...
Rupee Closed Weaker Against The US Dollar
The rupee weakened by five paise to close at 85.83 against the US dollar. The Indian rupee had declined to a fresh low against the US dollar during th...
Table Space Founder Amit Banerji Dies Of Heart Attack At Age Of 45
Amit Banerji, the founder, chairman and chief executive officer of managed workspace provider Table Space, died after suffering from a heart attack, r...
War Fatigue, Economic Breakdown Or Pro-West? Why Syria's Al-Sharaa Is Seen Soft On Israel
The strategic positions have been used by Israeli forces to carry out hundreds of strikes to destroy Syria's military infrastructure. In 2011, be...
Popular Questions
What is the Market Cap of lincoln?
The market capitalization of Lincoln Pharmaceuticals Limited is ₹1,612 Cr as of 05 Feb 2025.
What are the PE and PB ratios of Lincoln Pharmaceuticals Limited?
The PE and PB ratios of Lincoln Pharmaceuticals Limited are Not Available and 2.719121 respectively as of 05 Feb 2025.
What is the 52 Week High of Lincoln Pharmaceuticals Limited?
The 52-week high of Lincoln Pharmaceuticals Limited is ₹979.5 as of 05 Feb 2025.
What is the 52 Week Low of Lincoln Pharmaceuticals Limited?
The 52-week low of Lincoln Pharmaceuticals Limited is ₹534.8 as of 05 Feb 2025.
What are the earnings per share (EPS) for Lincoln Pharmaceuticals Limited?
The Earnings Per Share (EPS) of Lincoln Pharmaceuticals Limited is ₹48.24 as per the most recent quarterly results available on Fincept.
What is the ROE (Return on Equity) of Lincoln Pharmaceuticals Limited?
The Return on Equity (ROE) of Lincoln Pharmaceuticals Limited is 16.54% as per the most recent financial year data. Explore more on Fincept.